United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Seven Eight Capital LP

Seven Eight Capital LP lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 44.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,585 shares of the biotechnology company’s stock after selling 2,107 shares during the quarter. Seven Eight Capital LP’s holdings in United Therapeutics were worth $823,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of UTHR. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at about $100,519,000. LSV Asset Management lifted its stake in United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Swedbank AB acquired a new stake in United Therapeutics during the first quarter valued at approximately $97,316,000. Nordea Investment Management AB boosted its holdings in United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Finally, Avidity Partners Management LP acquired a new position in United Therapeutics in the fourth quarter worth approximately $52,158,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Bank of America decreased their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. UBS Group boosted their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. TD Cowen raised their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Wells Fargo & Company boosted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Stock Performance

UTHR stock opened at $353.00 on Friday. The stock has a market cap of $15.66 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The firm has a 50 day simple moving average of $339.19 and a 200 day simple moving average of $291.68. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the firm earned $5.24 earnings per share. The company’s revenue was up 19.8% on a year-over-year basis. Research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,622.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total value of $1,124,928.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,622.40. The disclosure for this sale can be found here. Insiders have sold a total of 110,922 shares of company stock valued at $36,541,398 in the last three months. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.